- Naked, Fusion Protein
- Antibody Fragment
- Conjugate
- Multi-specific
Monoclonal Antibody Therapeutic Market size was valued at USD 187.5 billion in 2023 and is poised to grow at a CAGR of 14.1% from 2024-2030. There will be around 70 monoclonal antibody products in the market by 2020 and the sales are estimated to be million which is considered as the key driver. Restrain which hung the global monoclonal antibody therapeutic are many drugs like Abagovomab, and Actoxumab in phase II and still waiting for approval which can be considered as a key challenge. The biggest opportunity is opened up due to various chronic disorders hence huge growth in the global monoclonal antibody therapeutic market is been expected. Monoclonal antibodies are a type of immunotherapy that is created in a lab and consists of several copies of a single antibody. The US Food and Drug Administration has approved several monoclonal antibodies to treat inflammation, cancer, and other disorders (FDA). Monoclonal antibodies are classified as murine, chimeric, humanized, or human, depending on the source. Murine antibodies are produced solely from a murine source, whereas chimeric antibodies have variable murine origins and constant human origins.
Monoclonal Antibody Therapeutic Market Key Developments:
- In April 2019, Outlook Therapeutics announced the U.S. FDA acceptance and activation of the Investigational New Drug (IND) application for ONS-5010, an innovative monoclonal antibody (mAb) therapeutic product candidate being developed for wet age-related macular degeneration (wet AMD), diabetic macular edema (DME) and branch retinal vein occlusion (BRVO).
- In May 2019, CASI Pharmaceuticals, a U.S. pharmaceutical company announced the signing of a license agreement for exclusive worldwide rights to the investigational anti-CD38 monoclonal antibody (Mab) TSK011010 program from Black Belt Therapeutics Limited.
Monoclonal Antibody Therapeutics Market Summary
Study Period
2024-2030
Base Year
2023
CAGR
14.1%
Largest Market
North America
Fastest Growing Market
Asia Pacific
Monoclonal Antibody Therapeutics Market Dynamics
It is noticed that the global monoclonal antibody market is influenced mainly by the number of cancer patients which is the key factor causing the monoclonal antibody market to grow. According to WHO (World Health Organization) around 18.1 million new cases have been reported and 96 million death rates have been observed due to cancer. Monoclonal antibody therapeutic market is considered to be a lifesaving innovation and the market is estimated to be valued in huge amount by 2026. 100 monoclonal antibodies have been designated as drug and 64 monoclonal antibodies have been approved by USFDA. There are a lot of pipeline drugs related to cancer waiting for the approval and that would intensify the growth of monoclonal antibody therapeutic market.
North-America Got Significant Share
Monoclonal Antibody Therapeutics Market Regional Analysis
North America contributed major revenue followed by Europe and Asia Pacific. In 2019, North America region accounted huge growth rate and is anticipated to grow with a forecast year. For instance, developed and established healthcare infrastructure support from the government for R&D activity may contribute the revenue growth of market. According to Centre for Disease Control and Prevention 6 in 12 adults in US have chronic disease. Europe is booming on the perspective of innovative products the market share to both together is estimated as 65%. However, it was evident that the monoclonal antibody therapeutic market gaining interest in developing nations. Asia pacific is growing on the perspective of faster growing market players which boost monoclonal antibody therapeutic market.
Latin America
Europe
Asia Pacific
Middle East
North America
Key Features of the Reports
- The report provides granular level information about the market size, regional market share, historic market (2019-2023), and forecast (2024-2030)
- The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
- The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
- The report tracks recent innovations, key developments, and start-up details that are actively working in the market
- The report provides a plethora of information about market entry strategies, regulatory framework, and reimbursement scenario
Monoclonal Antibody Therapeutics Market Segmentation
By Product Type
By Type
- Human Monoclonal Antibody
- Humanized Monoclonal Antibody
- Chimeric Monoclonal Antibody
- Murine Monoclonal Antibody
By End-User
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
Frequently Asked Questions
The monoclonal antibody therapeutics market size was valued at USD 187.5 billion in 2023 and is poised to grow at a CAGR of 14.1% from 2024-2030
ImmunoGen, Inc., Bayer AG, Biogen, Hoffmann-La Roche Ltd., GlaxoSmithKline Plc, Amgen, Inc., Pfizer Inc., Sanofi, Novartis AG, Merck, AbbVie
Asia Pacific is the fastest-growing region for monoclonal antibody therapeutics market
| 1.Executive Summary |
| 2.Global Monoclonal Antibody Therapeutics Market Introduction |
| 2.1.Global Monoclonal Antibody Therapeutics Market - Taxonomy |
| 2.2.Global Monoclonal Antibody Therapeutics Market - Definitions |
| 2.2.1.Product Type |
| 2.2.2.Type |
| 2.2.3.End User |
| 2.2.4.Region |
| 3.Global Monoclonal Antibody Therapeutics Market Dynamics |
| 3.1. Drivers |
| 3.2. Restraints |
| 3.3. Opportunities/Unmet Needs of the Market |
| 3.4. Trends |
| 3.5. Product Landscape |
| 3.6. New Product Launches |
| 3.7. Impact of COVID 19 on Market |
| 4.Global Monoclonal Antibody Therapeutics Market Analysis, 2019 - 2023 and Forecast 2024 - 2030 |
| 4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) |
| 4.3. Market Opportunity Analysis |
| 5.Global Monoclonal Antibody Therapeutics Market By Product Type, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 5.1. Naked, Fusion Protein |
| 5.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 5.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.1.3. Market Opportunity Analysis |
| 5.2. Antibody Fragment |
| 5.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 5.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.2.3. Market Opportunity Analysis |
| 5.3. Conjugate |
| 5.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 5.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.3.3. Market Opportunity Analysis |
| 5.4. Multi-specific |
| 5.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 5.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.4.3. Market Opportunity Analysis |
| 6.Global Monoclonal Antibody Therapeutics Market By Type, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 6.1. Human Monoclonal Antibody |
| 6.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 6.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.1.3. Market Opportunity Analysis |
| 6.2. Humanized Monoclonal Antibody |
| 6.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 6.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.2.3. Market Opportunity Analysis |
| 6.3. Chimeric Monoclonal Antibody |
| 6.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 6.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.3.3. Market Opportunity Analysis |
| 6.4. Murine Monoclonal Antibody |
| 6.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 6.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.4.3. Market Opportunity Analysis |
| 7.Global Monoclonal Antibody Therapeutics Market By End User, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 7.1. Hospital Pharmacy |
| 7.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 7.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.1.3. Market Opportunity Analysis |
| 7.2. Retail Pharmacy |
| 7.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 7.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.2.3. Market Opportunity Analysis |
| 7.3. Online Pharmacy |
| 7.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 7.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.3.3. Market Opportunity Analysis |
| 8.Global Monoclonal Antibody Therapeutics Market By Region, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 8.1. North America |
| 8.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 8.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.1.3. Market Opportunity Analysis |
| 8.2. Europe |
| 8.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 8.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.2.3. Market Opportunity Analysis |
| 8.3. Asia Pacific (APAC) |
| 8.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 8.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.3.3. Market Opportunity Analysis |
| 8.4. Middle East and Africa (MEA) |
| 8.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 8.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.4.3. Market Opportunity Analysis |
| 8.5. Latin America |
| 8.5.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 8.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.5.3. Market Opportunity Analysis |
| 9.North America Monoclonal Antibody Therapeutics Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 9.1. Product Type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 9.1.1.Naked, Fusion Protein |
| 9.1.2.Antibody Fragment |
| 9.1.3.Conjugate |
| 9.1.4.Multi-specific |
| 9.2. Type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 9.2.1.Human Monoclonal Antibody |
| 9.2.2.Humanized Monoclonal Antibody |
| 9.2.3.Chimeric Monoclonal Antibody |
| 9.2.4.Murine Monoclonal Antibody |
| 9.3. End User Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 9.3.1.Hospital Pharmacy |
| 9.3.2.Retail Pharmacy |
| 9.3.3.Online Pharmacy |
| 9.4. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 9.4.1.United States of America (USA) |
| 9.4.2.Canada |
| 10.Europe Monoclonal Antibody Therapeutics Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 10.1. Product Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.1.1.Naked, Fusion Protein |
| 10.1.2.Antibody Fragment |
| 10.1.3.Conjugate |
| 10.1.4.Multi-specific |
| 10.2. Type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.2.1.Human Monoclonal Antibody |
| 10.2.2.Humanized Monoclonal Antibody |
| 10.2.3.Chimeric Monoclonal Antibody |
| 10.2.4.Murine Monoclonal Antibody |
| 10.3. End User Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.3.1.Hospital Pharmacy |
| 10.3.2.Retail Pharmacy |
| 10.3.3.Online Pharmacy |
| 10.4. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.4.1.Germany |
| 10.4.2.France |
| 10.4.3.Italy |
| 10.4.4.United Kingdom (UK) |
| 10.4.5.Spain |
| 11.Asia Pacific (APAC) Monoclonal Antibody Therapeutics Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 11.1. Product Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.1.1.Naked, Fusion Protein |
| 11.1.2.Antibody Fragment |
| 11.1.3.Conjugate |
| 11.1.4.Multi-specific |
| 11.2. Type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.2.1.Human Monoclonal Antibody |
| 11.2.2.Humanized Monoclonal Antibody |
| 11.2.3.Chimeric Monoclonal Antibody |
| 11.2.4.Murine Monoclonal Antibody |
| 11.3. End User Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.3.1.Hospital Pharmacy |
| 11.3.2.Retail Pharmacy |
| 11.3.3.Online Pharmacy |
| 11.4. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.4.1.China |
| 11.4.2.India |
| 11.4.3.Australia and New Zealand (ANZ) |
| 11.4.4.Japan |
| 11.4.5.Rest of APAC |
| 12.Middle East and Africa (MEA) Monoclonal Antibody Therapeutics Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 12.1. Product Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.1.1.Naked, Fusion Protein |
| 12.1.2.Antibody Fragment |
| 12.1.3.Conjugate |
| 12.1.4.Multi-specific |
| 12.2. Type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.2.1.Human Monoclonal Antibody |
| 12.2.2.Humanized Monoclonal Antibody |
| 12.2.3.Chimeric Monoclonal Antibody |
| 12.2.4.Murine Monoclonal Antibody |
| 12.3. End User Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.3.1.Hospital Pharmacy |
| 12.3.2.Retail Pharmacy |
| 12.3.3.Online Pharmacy |
| 12.4. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.4.1.GCC Countries |
| 12.4.2.South Africa |
| 12.4.3.Rest of MEA |
| 13.Latin America Monoclonal Antibody Therapeutics Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 13.1. Product Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 13.1.1.Naked, Fusion Protein |
| 13.1.2.Antibody Fragment |
| 13.1.3.Conjugate |
| 13.1.4.Multi-specific |
| 13.2. Type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 13.2.1.Human Monoclonal Antibody |
| 13.2.2.Humanized Monoclonal Antibody |
| 13.2.3.Chimeric Monoclonal Antibody |
| 13.2.4.Murine Monoclonal Antibody |
| 13.3. End User Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 13.3.1.Hospital Pharmacy |
| 13.3.2.Retail Pharmacy |
| 13.3.3.Online Pharmacy |
| 13.4. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 13.4.1.Brazil |
| 13.4.2.Mexico |
| 13.4.3.Rest of LA |
| 14. Competition Landscape |
| 14.1. Market Player Profiles (Introduction, Brand/Product Sales, Financial Analysis, Product Offerings, Key Developments, Collaborations, M & A, Strategies, and SWOT Analysis) |
| 14.2.1.ImmunoGen, Inc. |
| 14.2.2.Bayer AG |
| 14.2.3.Biogen |
| 14.2.4.Hoffmann-La Roche Ltd. |
| 14.2.5.GlaxoSmithKline Plc |
| 14.2.6.Amgen, Inc. |
| 14.2.7.Pfizer Inc. |
| 14.2.8.Sanofi |
| 14.2.9.Novartis AG |
| 14.2.10.Merck |
| 14.2.11.AbbVie |
| 15. Research Methodology |
| 16. Appendix and Abbreviations |
- ImmunoGen, Inc.
- Bayer AG
- Biogen
- Hoffmann-La Roche Ltd.
- GlaxoSmithKline Plc
- Amgen, Inc.
- Pfizer Inc.
- Sanofi
- Novartis AG
- Merck
- AbbVie